Teleflex Subsidiary Faces Federal False Claims Investigation
Urology device developer NeoTract, which Teleflex purchased in 2017, is now under scrutiny for potential FCA violations.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
The medical device-maker says it will lose millions by the end of the fiscal year because Georgia regulators have temporarily shut down Sterigenics’ ethylene oxide sterilization (EtO) facility near Atlanta. With no news on when it will reopen, the company says it may lose even more money next year.
The resolution of a May 2020 warning letter to a breast implant manufacturer accounted for the only device-related close-out latter issued this month.